Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 01, 2024 10:00 ET | Source: Genmab A/S

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

Media Release COPENHAGEN, Denmark, and MAINZ, Germany; June 1, 2024 Initial data from the ongoing Phase 2 trial showed a 12-month overall survival (OS) rate of 69% and median overall survival...
May 27, 2024 10:16 ET | Source: Genmab A/S

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; May 27, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion...
May 23, 2024 17:00 ET | Source: Genmab A/S

Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

Media ReleaseCOPENHAGEN, Denmark; May 23, 2024 Six oral and poster presentations will highlight breadth of clinical program and potential utility of epcoritamab-bysp in patients with...
May 21, 2024 11:06 ET | Source: Genmab A/S

Genmab Completes Acquisition of ProfoundBio

Company Announcement Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cashAcquisition gives Genmab worldwide rights to three candidates in clinical development, including...
May 21, 2024 07:19 ET | Source: Genmab A/S

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; May 21, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion...
May 14, 2024 10:02 ET | Source: Genmab A/S

Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress

Media ReleaseCOPENHAGEN, Denmark; May 14, 2024 Sixteen abstracts accepted for presentation and publication demonstrate depth and breadth of comprehensive epcoritamab development programThree oral...
May 13, 2024 10:09 ET | Source: Genmab A/S

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; May 13, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5...
May 07, 2024 14:27 ET | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; May 7, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 6,959 shares as a consequence of the exercise of employee warrants. ...
May 06, 2024 10:01 ET | Source: Genmab A/S

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; May 6, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion...
May 02, 2024 11:01 ET | Source: Genmab A/S

Genmab Announces Financial Results for the First Quarter of 2024

May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right